Spotlight on medicines: Denosumab
Denosumab is the first in a new class of medicines for the treatment of osteoporosis. But, considering that there are other well established treatment options, what is denosumab’s place in therapy?
The treatment options for osteoporosis in patients who are not able to tolerate or comply with administration instructions for bisphosphonates are limited.
Denosumab is a novel agent that offers a cost-effective alternative to bisphosphonates for the treatment of osteoporosis in postmenopausal women.
Full text article available to read as a PDF (900K) file.
Wasim Baqir and Carmel Copeland are senior clinical pharmacists at Northumbria Healthcare NHS Foundation Trust.
Contribute to "Spotlight on medicines"
This Clinical Pharmacist series looks at prominent or recently launched medicines or classes of drugs. Comments on this or other articles are welcomed in the form of personal feedback to the editor or correspondence to Clinical Pharmacist.
Pharmacists who have ideas for the series or wish to write about medicines are invited to contact the editor.
Tel: +44 (0)20 7572 2425
Citation: Clinical Pharmacist URI: 11049427
Recommended from Pharmaceutical Press